Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)

被引：0
|
作者：
Woerle, H. J. [1 ]
Neubacher, D. [2 ]
Patel, S. [3 ]
von Eynatten, M. [1 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[3] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2013年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age ≥70 years) with type 2 diabetes
    Woerle, H. -J.
    Neubacher, D.
    Patel, S.
    von Eynatten, M.
    DIABETOLOGIA, 2012, 55 : S350 - S350
  • [2] Efficacy and Safety of Linagliptin in Elderly Patients (≥ 70 Years) With Type 2 Diabetes
    Barnett, Anthony
    Huisman, Holger
    Jones, Russell
    Von Eynatten, Maximilian
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A260 - A261
  • [3] Efficacy and Safety of Linagliptin as Add-On Therapy to Basal Insulin in Patients With Type 2 Diabetes
    Yki-Jarvinen, Hannele
    Duran-Garcia, Santiago
    Pinnetti, Sabine
    Bhattacharya, Sudipta
    Thiemann, Sandra
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A255 - A255
  • [4] Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in patients with type 2 diabetes
    Lee, J.
    Duran-Garcia, S.
    Yki-Jarvinen, H.
    Rosenstock, J.
    Hehnke, U.
    Thiemann, S.
    Patel, S.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S355 - S355
  • [5] Efficacy and Safety of Linagliptin/Metformin Fixed-Dose Combination (FDC) as Initial Therapy in Asian Patients with Type 2 Diabetes (T2D) and Severe Hyperglycemia
    Mu, Yiming
    Pan, Changyu
    Fan, Bei
    Hehnke, Uwe
    Gong, Yan
    DIABETES, 2015, 64 : A315 - A315
  • [6] Efficacy and Safety of standard Insulin Therapy for hospitalized Patients in the Age of <70 and ≥70 Years with Diabetes Mellitus Type 2
    Neubauer, Katharina M.
    Mader, Julia K.
    Aberer, Felix
    Schaupp, Lukas
    Donsa, Klaus
    Augustin, Thomas
    Beck, Peter
    Pieber, Thomas R.
    Plank, Johannes
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 : S148 - S148
  • [7] Glycemic Control and Adherence to Basal Insulin Therapy in Taiwanese Patients with Type 2 Diabetes (T2D)
    Chien, Ming-Nan
    Chen, Yen-Ling
    Hung, Yi-Jen
    Wang, Shu-Yi
    Lu, Wen-Tsung
    Chen, Chih-Hung
    Lin, Ching-Ling
    Huang, Tze-Pao
    Tsai, Ming-Han
    Tseng, Wei-Kung
    Wu, Ta-Jen
    Ho, Cheng
    Lin, Wen-Yu
    Chen, Bill
    Chuang, Lee-Ming
    DIABETES, 2014, 63 : A600 - A600
  • [8] Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes
    Duran-Garcia, S.
    Lee, J.
    Yki-Jarvinen, H.
    Rosenstock, J.
    Hehnke, U.
    Thiemann, S.
    Patel, S.
    Woerle, H. -J.
    DIABETIC MEDICINE, 2016, 33 (07) : 926 - 933
  • [9] Efficacy and Safety of Linagliptin/Metformin Fixed-Dose Combination (FDC) as Initial Therapy in Drug-Naive Asian Patients with Type 2 Diabetes (T2D)
    Pan, Changyu
    Mu, Yiming
    Fan, Bei
    Hehnke, Uwe
    Gong, Yan
    DIABETES, 2015, 64 : A323 - A323
  • [10] Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)-A Pooled Comprehensive Posthoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Johansen, Odd Erik
    Woerle, Hans J.
    DIABETES, 2014, 63 : A274 - A274
12345